Yet, the authors said that even if only 20 percent of hypertensive patients could self-monitor their condition, that would represent around 4 percent of the British population, or 2 million people.

In an accompanying editorial, Dr. Gbenga Ogedegbe, an associate professor at the New York University School of Medicine, recognized the findings could "profoundly affect" treatment of the condition while also acknowledging uncertainties about how broadly they could be applied.


"Although findings of the TASMINH2 trial suggest that self-titration of antihypertensive drugs has come of age in terms of its feasibility, safety, and efficacy," Ogedegbe wrote, "its widespread dissemination into primary care practices might be premature until these findings are replicated by other investigators, especially in low-income, low-literate patients who receive care in low-resource, non-academic settings."

Back to HCB News

More Industry Headlines